GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Drug: BLYG8824A
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04468607
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇪🇸Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid TumorsColorectal Cancer
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04449874
- Locations
- 🇮🇱
Sheba Medical Center - PPDS, Ramat Gan, Israel
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
- Conditions
- Relapsed Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04434469
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇴Oslo Universitetssykehus HF; Ullevål sykehus, Oslo, Norway
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
- Conditions
- HER2-positive Breast Cancer
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT04395508
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
- Conditions
- Alzheimer Disease
- Interventions
- Diagnostic Test: [18F]GTP1
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04394845
- Locations
- 🇺🇸
Invicro, a Konica Minolta company, New Haven, Connecticut, United States
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT04386616
- Locations
- 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸Albany Medical Center, Albany, New York, United States
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT04377555
- Locations
- 🇺🇸
SUNY Upstate Medical Center, Syracuse, New York, United States
🇺🇸Neurology Specialists, Inc, Dayton, Ohio, United States
🇵🇷Centro Internacional De Mercadeo, Guaynabo, Puerto Rico
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT04372186
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇺🇸El Centro Regional Medical Center, El Centro, California, United States
🇺🇸Highland Hospital Oakland, Oakland, California, United States
A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: HP xenon (¹²⁹XE)
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04353661
- Locations
- 🇺🇸
Duke Asthma Allergy and Airway Center, Durham, North Carolina, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Procedure: ResectionDrug: SBRTDrug: Chemotherapy
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT04302025
- Locations
- 🇺🇸
University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Ellis Fischel Cancer Center, Columbia, Missouri, United States
🇺🇸UCSF Helen Diller Family CCC, San Francisco, California, United States